Core Viewpoint - Autonomix Medical, Inc. is enhancing its intellectual property portfolio with the issuance of U.S. Patent No. 12,295,646, which relates to a smart torquer device aimed at improving intravascular procedures, positioning the company for significant opportunities in a multi-billion-dollar market [1][2]. Group 1: Intellectual Property and Market Position - The company has over 80 issued patents and 40 pending applications, establishing a strong IP portfolio in nerve-sensing and modulation technologies [1]. - The newly issued '646 patent is designed to improve the manipulation of intravascular devices during minimally invasive procedures, integrating electronic components for better mechanical control and data communication [1][3]. - The smart torquer technology is expected to enhance control and signal integration in intravascular procedures, facilitating expansion into high-growth areas such as cardiology, neurosurgery, and interventional radiology [2]. Group 2: Technology and Applications - Autonomix's technology platform includes a catheter-based microchip sensing array that can detect and differentiate neural signals with greater sensitivity than existing technologies [4][6]. - The proprietary RF ablation technology allows for precision-guided interventions targeting specific nerves, which can address various diseases, including chronic pain and hypertension [4][7]. - Initial development efforts are focused on treating pain associated with pancreatic cancer, a condition currently lacking reliable treatment options [7].

Core Insights - Autonomix Medical, Inc. is set to present its technology and early proof-of-concept study results at EuroPCR 2025, a leading course in interventional cardiovascular medicine [1][4] - The presentation will focus on a catheter-based transvascular RF neural ablation technique aimed at alleviating severe pain associated with pancreatic cancer [2][6] Company Overview - Autonomix Medical, Inc. specializes in innovative medical device technologies targeting diseases of the nervous system, with a first-in-class platform that includes a catheter-based microchip sensing array [5][6] - The company's technology aims to enhance the detection and differentiation of neural signals, potentially enabling transvascular diagnosis and treatment of peripheral nervous system diseases [5][6] Technology Development - The initial focus of the technology is on treating pain, particularly in pancreatic cancer, which is known for causing severe discomfort and lacks effective treatment options [6] - The platform technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management [6]